Praxis precision medicines provides corporate update and reports first quarter 2025 financial results
On track for six major study readouts across four programs over the next 12 months ready to initiate pivotal studies in two developmental and epileptic encephalopathy (dee) programs in mid-year 2025: emerald for broad dees with relutrigine and embrave3 for scn2a gof with elsunersen vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability praxis to host a virtual investor event on friday, may 2, 2025 to discuss its dee portfolio [registration link] cash and investments of $472 million as of march 31, 2025, maintains runway into 2028 boston, may 02, 2025 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025. “we have made substantial progress in advancing our promising late-stage epilepsy portfolio and are firing on all cylinders through this unpredictable time in the industry,” said marcio souza, president and chief executive officer of praxis.
PRAX Ratings Summary
PRAX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission